1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Inhibrx, Inc.
  6. News
  7. Summary
    INBX   US45720L1070

INHIBRX, INC.

(INBX)
  Report
Real-time Estimate Cboe BZX  -  05/24 03:24:56 pm EDT
12.21 USD   -7.64%
05/16Inhibrx's Phase 1 Trial of INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency
MT
05/16INHIBRX, INC. : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
05/16INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency and Demonstrates Potential to Achieve Normal Functional Alpha-1 Antitrypsin Levels with Monthly Dosing
PR
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Health Care Stocks Still Trying to Overcome Midday Slide

01/25/2022 | 03:49pm EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. 0.18% 16.91 Delayed Quote.-8.51%
INHIBRX, INC. -7.83% 12.14 Delayed Quote.-69.73%
JOHNSON & JOHNSON 0.79% 180.93 Delayed Quote.4.89%
NASDAQ COMP. -2.72% 11218.77 Real-time Quote.-26.27%
SIERRA ONCOLOGY, INC. -0.01% 54.625 Delayed Quote.151.29%
All news about INHIBRX, INC.
05/16Inhibrx's Phase 1 Trial of INBRX-101 Shows Favorable Safety Profile in Patients with Al..
MT
05/16INHIBRX, INC. : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits ..
AQ
05/16INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficienc..
PR
05/16INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficienc..
CI
05/12Inhibrx, Inc. to Host Webcast Presentation of Topline Results from the Phase 1 Trial of..
CI
05/09Earnings Flash (INBX) INHIBRX Posts Q1 Revenue $929,000
MT
05/09INHIBRX, INC. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
05/09Inhibrx, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
04/25INHIBRX : Announces Formation of Scientific Advisory Board for INBRX-101 - Form 8-K
PU
04/25INHIBRX, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
More news
Analyst Recommendations on INHIBRX, INC.
More recommendations
Financials (USD)
Sales 2022 4,93 M - -
Net income 2022 -129 M - -
Net cash 2022 75,0 M - -
P/E ratio 2022 -4,16x
Yield 2022 -
Capitalization 516 M 516 M -
EV / Sales 2022 89,6x
EV / Sales 2023 52,4x
Nbr of Employees 109
Free-Float 68,4%
Chart INHIBRX, INC.
Duration : Period :
Inhibrx, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INHIBRX, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 13,22 $
Average target price 47,00 $
Spread / Average Target 256%
EPS Revisions
Managers and Directors
Mark P. Lappe Chairman & Chief Executive Officer
Kelly Devine Deck Chief Financial Officer
Brendan P. Eckelman Chief Scientific Officer
Ashraf Amanullah Chief Technical Operations Officer & Executive VP
Jeffrey Jensen Executive Vice President-Clinical Operations
Sector and Competitors
1st jan.Capi. (M$)
INHIBRX, INC.-69.73%516
GILEAD SCIENCES, INC.-12.33%79 850
REGENERON PHARMACEUTICALS, INC.7.98%73 473
VERTEX PHARMACEUTICALS22.20%68 632
WUXI APPTEC CO., LTD.-17.77%42 378
BIONTECH SE-36.69%39 666